Factors reported to be associated with improved local control of SRS-treated brain metastases from HER-2 positive breast cancer include lapatinib concurrent with SRS [3, 28, 29], smaller lesion volume [28, 29], and higher prescription dose [28]. This evidence concerns the gene ERBB2 and breast cancer.